Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TTLL13 (Tubulin tyrosine ligase like 13) is an ATP-dependent polyglutamylase enzyme that catalyzes the elongation phase of polyglutamylation on tubulin, mainly modifying the alpha-tubulin tail in the cytosol and ciliary basal bodies[3]. This modification affects microtubule dynamics and stability, influencing diverse cellular functions, including cell division, intracellular transport, and the formation of specialized structures such as cilia and flagella[2][3]. Dysfunction in tubulin polyglutamylases and related tubulin modifications is linked to cancer progression and neurodevelopmental disorders due to abnormal microtubule regulation[1][2]. TTLL13 is structurally related to other TTLL family enzymes and contains characteristic ATP-grasp domains that facilitate its catalytic activity[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin tyrosine ligase like 13 (TTLL13).